European stocks were mixed in early Monday trade after finishing last week on a positive note, with regional data showing the UK economy expanded in the third quarter, matching estimates.

The DAX index in Germany climbed 0.1%, the CAC 40 in France fell 0.3% and the FTSE 100 in the U.K. dropped 0.3%. 

Europe round up

UK economy maintained its growth rate of 0.1% quarter-on-quarter in the final Q3 2025 GDP figures released Monday. While the headline figure remained unchanged from earlier estimates, the composition of growth showed shifts toward the private sector.

The breakdown revealed less reliance on government spending than previously thought, with government investment revised significantly downward from an initial estimate of 3.6% growth to a 1.8% decline.

Saipem SpA (BIT:SPMI) shares climbed about 4% in Milan trading after the Italian engineering group announced it had secured a major offshore contract for Qatar’s flagship LNG expansion project.

The company revealed it had been awarded an offshore engineering, procurement, construction and installation (EPCI) contract by QatarEnergy LNG. Saipem will be working in partnership with China’s Offshore Oil Engineering Co on the project.

In other corporate news, Telecom Italia’s (BIT:TLIT) board approved a proposal to convert the company’s savings shares into ordinary stock and to reduce its share capital. The proposal will be put to shareholders at meetings scheduled for January 28.

In acquisition news, a group of private equity firms led by Permira and Warburg Pincus has agreed to acquire Clearwater Analytics in a deal valuing the company at $8.4 billion including debt. Clearwater investors would receive $24.55 a share for an equity value of about $7 billion.

Meanwhile, GSK plc (LON:GSK) has entered into an agreement with the U.S. government to reduce prescription medicine costs for American patients, particularly for its respiratory portfolio that treats over 40 million Americans with asthma and COPD.

The agreement fulfills all four requests made by President Trump in his July 31 letter. GSK will lower prices of certain medicines in Medicaid and adopt a more balanced pricing approach for new product launches.